Сравнение методов
Просматривайте выбранные методы рядом; строки с различиями подсвечены.
| Регрессионный дизайн разрыва (Policy Evaluation Regression Discontinuity Design)× | Метод подбора на основе оценки склонности× | |
|---|---|---|
| Область≠ | Причинно-следственный вывод | Статистика исследований |
| Семейство≠ | Regression model | Process / pipeline |
| Год появления≠ | 1960; policy evaluation applications widespread from 2000s | 1983 |
| Автор метода≠ | Thistlethwaite & Campbell (1960); popularized in policy evaluation by Lee & Lemieux (2010) | Paul Rosenbaum and Donald Rubin |
| Тип≠ | Quasi-experimental causal design | Method |
| Основополагающий источник≠ | Lee, D. S., & Lemieux, T. (2010). Regression Discontinuity Designs in Economics. Journal of Economic Literature, 48(2), 281-355. DOI ↗ | Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55. DOI ↗ |
| Другие названия≠ | Policy RDD, RD design in policy evaluation, regression discontinuity policy analysis, RDD policy impact | PSM, propensity score weighting, covariate balance |
| Связанные≠ | 5 | 3 |
| Сводка≠ | Policy Evaluation Regression Discontinuity Design (Policy RDD) exploits a known eligibility threshold in a policy rule to estimate the causal effect of that policy on outcomes. Units just below the cutoff serve as a credible comparison group for units just above it, making RDD one of the most transparent quasi-experimental strategies for assessing what a policy actually achieves. | Propensity score matching (PSM) is a method for reducing confounding bias in observational studies by balancing baseline characteristics between treatment groups, simulating randomization. Developed by Rosenbaum and Rubin (1983), it estimates the probability of receiving treatment given observed covariates, then matches or weights treated and control individuals with similar treatment probabilities. Widely used in medicine, epidemiology, and policy evaluation when randomized trials are infeasible or unethical, enabling estimation of treatment effects while controlling for selection bias. |
| ScholarGateНабор данных ↗ |
|
|